Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	75.62	-	-	-	-
Cost of Revenue	112.86	103.37	-	-	-
Gross Profit	-37.24	-103.37	-	-	-
Selling, General & Admin	43.87	39.94	35.12	15.73	4.01
Research & Development	-	-	77.26	57.16	24.01
Operating Expenses	43.87	39.94	112.38	72.88	28.01
Operating Income	-81.11	-143.31	-112.38	-72.88	-28.01
Interest & Investment Income	10.57	9.33	3.76	0.05	0.01
Currency Exchange Gain (Loss)	0.42	-0.93	0.01	-0.16	-0.2
Other Non Operating Income (Expenses)	-	-	-	-0.96	-7.68
EBT Excluding Unusual Items	-70.13	-134.91	-108.61	-73.96	-35.88
Gain (Loss) on Sale of Investments	-	-0.13	-	-	-
Gain (Loss) on Sale of Assets	-	0.02	0.11	-	-
Pretax Income	-70.13	-135.01	-108.5	-73.96	-35.88
Income Tax Expense	2.57	0.34	-	-	-
Net Income	-72.7	-135.35	-108.5	-73.96	-35.88
Net Income to Common	-72.7	-135.35	-108.5	-73.96	-35.88
Shares Outstanding (Basic)	74	51	47	25	2
Shares Outstanding (Diluted)	74	51	47	25	2
Shares Change (YoY)	43.80%	8.83%	88.91%	1548.09%	7.11%
EPS (Basic)	-0.98	-2.63	-2.30	-2.96	-23.65
EPS (Diluted)	-0.98	-2.63	-2.30	-2.96	-23.65
Free Cash Flow	38.01	-62.84	-105.38	-69.1	-26.44
Free Cash Flow Per Share	0.51	-1.22	-2.23	-2.76	-17.43
Gross Margin	-49.25%	-	-	-	-
Operating Margin	-107.26%	-	-	-	-
Profit Margin	-96.14%	-	-	-	-
Free Cash Flow Margin	50.26%	-	-	-	-
EBITDA	-72.99	-137.09	-108.64	-70.75	-27.47
EBITDA Margin	-96.52%	-	-	-	-
D&A For EBITDA	8.12	6.22	3.75	2.13	0.54
EBIT	-81.11	-143.31	-112.38	-72.88	-28.01
EBIT Margin	-107.26%	-	-	-	-

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q